CXCL12 and cancer: Inhibiting CXCL12 action through ulocuplumab results in the inhibition of downstream pro-survival signals (PI3K/AKT, MAPK), reduction in maintenance of cancer stem cells, and increased chemotherapeutic-triggered apoptosis [22].